Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details)

v3.23.2
Summary of Significant Accounting Policies (Details) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Summary of Significant Accounting Policies (Details) [Line Items]          
Foreign currency translation description     The functional currency of certain subsidiaries was the British Pound (“GBP”) (1.2680 and 1.2098 GBP to 1 US dollar, each as of June 30, 2023 and December 31, 2022, respectively) for balance sheet accounts, while expense accounts are translated at the weighted average exchange rate for the period (1.2520 and 1.2571 GBP to 1 US dollar for each of the three months ended June 30, 2023 and 2022, respectively, and 1.2335 and 1.2995 GBP to 1 US dollar each for the six months ended June 30, 2023 and 2022, respectively). Equity accounts are translated at historical exchange rates. The resulting translation adjustments are recognized in stockholders’ equity as a component of accumulated other comprehensive (loss) income.    
Comprehensive loss $ (15,267) $ (1,908,051) $ (14,604) $ (2,636,132)  
Foreign currency transaction gain (losses) $ (1,467) $ 22 (350) $ (120)  
Carrying amount     $ 9,063,000   $ 12,405,084
Fair market value         9,063,000
Assets impaired         3,342,084
Total asset balance         9,063,000
Minimum [Member]          
Summary of Significant Accounting Policies (Details) [Line Items]          
Carrying amount         1,462,084
Fair market value         0
Assets exceeded market values         1,462,084
Asset balances CBR pharma subsidiary         0
Maximum [Member]          
Summary of Significant Accounting Policies (Details) [Line Items]          
Carrying amount         10,943,000
Fair market value         9,063,000
Assets exceeded market values         1,880,000
Asset balances CBR pharma subsidiary         $ 9,063,000